Editorial Transparency
Corrections & Updates
Medicine changes, and so does our content. Spot something that needs fixing, or have a topic in mind? Submit it below — every material correction and clinical update we make is publicly logged underneath, with the evidence that prompted it.
Corrections & Feedback
Spot a discrepancy in an analysis, or have an idea for something we should build? Let us know below.
A real pharmacist reads every submission.
Regarding: Gaps in VAP Prevention Knowledge Among ICU Staff (PMID 42347268)
Correction
2026-07-08
Andexanet alfa (Andexxa) was voluntarily withdrawn from the US market effective December 22, 2025 after the ANNEXA-I trial showed a net increase in thromboembolic events versus usual care in intracranial hemorrhage. Our Direct Oral Anticoagulants reference now lists 4-factor PCC (Kcentra) as the practical option for factor Xa inhibitor reversal, with a note on the withdrawal.
Correction
2026-07-08
The reduced-efficacy warning for edoxaban in patients with CrCl >95 mL/min is derived from the ENGAGE AF-TIMI 48 trial. An earlier version incorrectly attributed it to a different study. The DOAC reference has been corrected.
Update
2026-07-08
Guidance updated to reflect the 2023 ACORN randomized trial, which found no difference in acute kidney injury versus cefepime, and the pseudotoxicity debate (creatinine-secretion interference). Our Vancomycin TDM and Beta-lactam references now present this as an unsettled association rather than established fact.
Update
2026-07-08
Corrected the recommendation grades in the Vasopressors reference: vasopressin add-on is a weak (suggest) recommendation, and norepinephrine first-line is supported by moderate-quality evidence, per SSC 2021.
Update
2026-07-08
The DOAC renal-dosing table now reflects FDA labeling for apixaban in ESRD/hemodialysis (5 mg BID, or 2.5 mg BID if age ≥80 or ≤60 kg), with a note that this is based on pharmacokinetic data rather than outcomes trials.